GlassScriptPhysician profile
Andrew J Adelson
NPI 1932107018
$5,956.03
in general payments reported to CMS, 2019-2025
27 companies · $897 in 2025
The $897 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,106 · 2020: $984 · 2021: $626 · 2022: $534 · 2023: $823 · 2024: $986 · 2025: $897.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,695 · Travel and Lodging: $10.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,695.49 |
| Travel and Lodging | $10.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $1,007.15 | 2019-2022 | |
| Abbvie INC. | $656.08 | 2022-2025 | Vuity, Lumigan, Alphagan P |
| Tarsus Pharmaceuticals, INC. | $467.23 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $463.48 | 2019-2023 | |
| New World Medical,INC. | $390.00 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $351.30 | 2019-2021 | |
| Alcon Vision LLC | $299.73 | 2019-2025 | Clareon, Rocklatan, Clareon Panoptix Pro |
| Sun Pharmaceutical Industries INC. | $290.43 | 2019-2025 | |
| Glaukos Corporation | $281.06 | 2024-2025 | Idosetr |
| Oyster Point Pharma, INC. | $271.16 | 2023-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb Americas INC. | $265.76 | 2022-2025 | Envista Mx60 Iol, Ic-8 Apthera Iol, Vyzulta |
| Sight Sciences, INC. | $159.62 | 2023-2025 | Sion Surgical Instrument, Omni Surgical System, Tearcare System |
| Biotissue Holdings INC. | $152.67 | 2019-2023 | |
| Kala Pharmaceuticals, INC. | $149.96 | 2019-2022 | |
| Shire North American Group INC | $140.08 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $138.13 | 2019-2020 | |
| Genentech USA, INC. | $126.88 | 2025 | Susvimo |
| Johnson & Johnson Surgical Vision, INC. | $65.09 | 2019 | |
| Rxsight INC | $60.89 | 2022 | |
| Dompe US, INC. | $49.21 | 2022-2024 | Oxervate |
| Astellas Pharma US INC | $34.10 | 2024 | Izervay |
| Carl Zeiss Meditec, INC. | $24.93 | 2019 | |
| Tearlab Corp | $24.81 | 2022 | |
| Mallinckrodt Hospital Products INC. | $24.75 | 2021 | |
| Thea Pharma INC. | $24.48 | 2024 | Iyuzeh |
| Harrow Eye, LLC | $22.05 | 2025 | Vevye |
| Oasis Medical, INC. | $15.00 | 2025 | Oasis Tears |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Adelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.